Submit Content
Get the latest delivered to your inbox
Privacy Policy

Biogen Included in 2022 Bloomberg Gender-Equality Index

Published 01-28-22

Submitted by Biogen

Bloomberg Gender Equality Index logo

We are proud to be included on the Bloomberg Gender Equality Index, a modified market capitalization-weighted index that aims to track the performance of public companies committed to transparency in gender-data reporting.

We recognize the role we play to foster a more inclusive future, including developing the next generation of female leaders at all levels of our organization.

Learn more about our progress in our DE&I report

For more information about Bloomberg’s Gender-Equality Index, please visit: www.bloomberg.com/gei.

Biogen Logo

Biogen

Biogen

At Biogen, our mission is clear: we are pioneers in neuroscience. Biogen discovers, develops and delivers worldwide innovative therapies for people living with serious neurological and neurodegenerative diseases as well as related therapeutic adjacencies. One of the world’s first global biotechnology companies, Biogen was founded in 1978 by Charles Weissmann, Heinz Schaller, Kenneth Murray and Nobel Prize winners Walter Gilbert and Phillip Sharp. Today Biogen has the leading portfolio of medicines to treat multiple sclerosis, has introduced the first approved treatment for spinal muscular atrophy, commercializes biosimilars of advanced biologics and is focused on advancing research programs in multiple sclerosis and neuroimmunology, Alzheimer’s disease and dementia, neuromuscular disorders, movement disorders, ophthalmology, immunology, neurocognitive disorders, acute neurology and pain. We routinely post information that may be important to investors on our website at www.biogen.com. To learn more, please visit www.biogen.com and follow us on social media - Twitter, LinkedIn, Facebook, YouTube.

More from Biogen

Join today and get the latest delivered to your inbox